In this week’s video, Dr. Brian GM Durie explains that the FDA will soon consider MRD-testing as a surrogate endpoint for both newly diagnosed and relapsed myeloma patients. 

It is very likely that the FDA will approve both tests—NGS and NGF—within the next 1–2 years.

Have a question? Submit it to

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at

Previous Post
Gene Editing, Regulating DNA Sequencing Tests, and How Your Body Gets Its Energy
Next Post
Can myeloma cells contaminate a patient’s stem cells that are harvested for transplant?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.